Monthly Archives: October 2014

Biosceptre appoints new Chief Scientific Officer

Appointment to accelerate commercialisation of lead products

Cambridge, UK, 20 October 2014. Biosceptre, the oncology company developing antibody products that target the nf-P2X7 receptor announces the appointment of Dr Shaun McNulty as Chief Scientific Officer (CSO).

Shaun’s appointment follows an organisational change as the Company progresses from product development to the next phase of product commercialisation. Shaun’s primary function will be to ensure that Biosceptre delivers successful clinical trials for BIL-010t (topical) and BIL-03s (systemic) anti-cancer programmes. The Directors of Biosceptre are pleased to announce the appointment of Shaun as CSO with immediate effect.

Shaun has a wealth of relevant leadership experience including over 18 years of managing development projects and teams within the Pharmaceutical and Biotechnology sectors. Shaun has held leadership positions at GSK, Syntaxin, and Pfizer, where he helped develop Lyrica pregabalin, to treat neuropathic pain and partial seizures. He has consulted for the Biotechnology sector over a 12 year period and has published broadly.

Shaun said: “I am pleased to become CSO at this exciting stage for Biosceptre, with the opportunity to progress human clinical trials to validate our positive findings from preclinical and clinical studies.”

Gavin Currie CEO, added: “I am delighted that Shaun has agreed to become CSO of Biosceptre. His wealth of experience will be enormously beneficial in taking Biosceptre’s programmes forward into the clinic and beyond.”

Media contact:

Daniel Barton
Biosceptre
media@biosceptre.com
+61 412 548 824
+1 650 249 4977